Psychemedics Corp.  

(Public, NASDAQ:PMD)   Watch this stock  
Find more results for PMD
+0.27 (1.19%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 22.04 - 23.15
52 week 13.00 - 27.45
Open 22.69
Vol / Avg. 65,697.00/21,055.00
Mkt cap 126.31M
P/E 15.41
Div/yield 0.15/2.61
EPS 1.49
Shares 5.46M
Beta 1.02
Inst. own 55%
Jul 24, 2017
Q2 2017 Psychemedics Corp Earnings Release (Estimated) Add to calendar
Apr 25, 2017
Q1 2017 Psychemedics Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 14.69% 17.13%
Operating margin 22.22% 25.94%
EBITD margin - 31.84%
Return on average assets 23.72% 28.38%
Return on average equity 37.53% 48.96%
Employees 206 -
CDP Score - -


125 Nagog Park Ste 200
ACTON, MA 01720-3451
United States - Map
+1-800-6288073 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Psychemedics Corporation (Psychemedics) provides hair testing for drugs of abuse, utilizing a hair analysis method involving digestion of hair, enzyme immunoassay (EIA) technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company operates in drug testing services segment. The Company is in the business of performing drug testing and reporting the results thereof. The Company's drug testing services include training for collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit tested of samples. The Company's primary application of its technology is as a testing service that analyzes hair samples for the presence of certain drugs of abuse. The Company's tests provide information that indicates the approximate amount of drug ingested, as well as historical data, which shows a pattern of individual drug use over a longer period of time.

Officers and directors

Raymond C. Kubacki Jr. Chairman of the Board, President, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Neil L. Lerner Vice President - Finance
Age: 48
Bio & Compensation  - Reuters
Michael I. Schaffer Ph.D. Vice President - Laboratory Operations
Age: 71
Bio & Compensation  - Reuters
James V. Dyke Corporate Vice President - Sales and Marketing
Age: 51
Bio & Compensation  - Reuters
A. Clinton Allen Independent Director
Age: 73
Bio & Compensation  - Reuters
Harry F. Connick Sr. Independent Director
Age: 90
Bio & Compensation  - Reuters
Walter S. Tomenson Jr. Independent Director
Age: 69
Bio & Compensation  - Reuters
Fred J. Weinert Independent Director
Age: 68
Bio & Compensation  - Reuters